AbbVie Inc.AbbVie Inc.AbbVie Inc.

AbbVie Inc.

No trades
See on Supercharts

Key facts today


AbbVie (ABBV) announced a regular quarterly dividend of $1.64 per share, scheduled for payment on November 14, 2025, to shareholders recorded as of October 15, 2025.
AbbVie has signed a global licensing deal with Glenmark Pharma, paying $700 million for rights to develop and market the blood cancer drug ISB 2001 in key regions.
Analyze the impactAnalyze the impact
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪375.50 B‬USD
2.11USD
‪4.24 B‬USD
‪56.33 B‬USD
‪1.76 B‬
Beta (1Y)
0.36
Employees (FY)
‪55 K‬
Change (1Y)
‪+5 K‬ +10.00%
Revenue / Employee (1Y)
‪1.02 M‬USD
Net income / Employee (1Y)
‪77.05 K‬USD

About AbbVie Inc.


CEO
Robert A. Michael
Website
Headquarters
North Chicago
Founded
2011
ISIN
US00287Y1091
FIGI
BBG0025Y4RY4
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Check out other big names from the same industry as ABBV.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
ABBV5068386
AbbVie Inc. 4.05% 21-NOV-2039
Yield to maturity
Maturity date
Nov 21, 2039
ABBV4911718
AbbVie Inc. 4.25% 21-NOV-2049
Yield to maturity
Maturity date
Nov 21, 2049
ABBV5759203
AbbVie Inc. 5.05% 15-MAR-2034
Yield to maturity
Maturity date
Mar 15, 2034
ABBV4693581
AbbVie Inc. 4.25% 14-NOV-2028
Yield to maturity
Maturity date
Nov 14, 2028
ABBV5068390
AbbVie Inc. 4.75% 15-MAR-2045
Yield to maturity
Maturity date
Mar 15, 2045
ABBV5758814
AbbVie Inc. 4.8% 15-MAR-2029
Yield to maturity
Maturity date
Mar 15, 2029
ABBV4998675
AbbVie Inc. 4.75% 15-MAR-2045
Yield to maturity
Maturity date
Mar 15, 2045
ABBV5759202
AbbVie Inc. 4.95% 15-MAR-2031
Yield to maturity
Maturity date
Mar 15, 2031
ABBV5068389
AbbVie Inc. 4.85% 15-JUN-2044
Yield to maturity
Maturity date
Jun 15, 2044
ABBV6009611
AbbVie Inc. 4.65% 15-MAR-2028
Yield to maturity
Maturity date
Mar 15, 2028
ABBV5068387
AbbVie Inc. 4.25% 21-NOV-2049
Yield to maturity
Maturity date
Nov 21, 2049

See all ABBV bonds 

Frequently Asked Questions


The current price of ABBV is 209.79 USD — it has decreased by −0.21% in the past 24 hours. Watch AbbVie Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange AbbVie Inc. stocks are traded under the ticker ABBV.
ABBV stock has risen by 2.19% compared to the previous week, the month change is a 7.77% rise, over the last year AbbVie Inc. has showed a 8.44% increase.
We've gathered analysts' opinions on AbbVie Inc. future price: according to them, ABBV price has a max estimate of 255.00 USD and a min estimate of 170.00 USD. Watch ABBV chart and read a more detailed AbbVie Inc. stock forecast: see what analysts think of AbbVie Inc. and suggest that you do with its stocks.
ABBV reached its all-time high on Mar 10, 2025 with the price of 218.66 USD, and its all-time low was 32.51 USD and was reached on Dec 17, 2012. View more price dynamics on ABBV chart.
See other stocks reaching their highest and lowest prices.
ABBV stock is 2.38% volatile and has beta coefficient of 0.36. Track AbbVie Inc. stock price on the chart and check out the list of the most volatile stocks — is AbbVie Inc. there?
Today AbbVie Inc. has the market capitalization of ‪375.50 B‬, it has increased by 1.37% over the last week.
Yes, you can track AbbVie Inc. financials in yearly and quarterly reports right on TradingView.
AbbVie Inc. is going to release the next earnings report on Oct 24, 2025. Keep track of upcoming events with our Earnings Calendar.
ABBV earnings for the last quarter are 2.97 USD per share, whereas the estimation was 2.88 USD resulting in a 3.12% surprise. The estimated earnings for the next quarter are 3.26 USD per share. See more details about AbbVie Inc. earnings.
AbbVie Inc. revenue for the last quarter amounts to ‪15.42 B‬ USD, despite the estimated figure of ‪15.03 B‬ USD. In the next quarter, revenue is expected to reach ‪15.55 B‬ USD.
ABBV net income for the last quarter is ‪928.00 M‬ USD, while the quarter before that showed ‪1.28 B‬ USD of net income which accounts for −27.27% change. Track more AbbVie Inc. financial stats to get the full picture.
Yes, ABBV dividends are paid quarterly. The last dividend per share was 1.64 USD. As of today, Dividend Yield (TTM)% is 3.04%. Tracking AbbVie Inc. dividends might help you take more informed decisions.
AbbVie Inc. dividend yield was 3.54% in 2024, and payout ratio reached 263.15%. The year before the numbers were 3.87% and 220.33% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 9, 2025, the company has ‪55 K‬ employees. See our rating of the largest employees — is AbbVie Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AbbVie Inc. EBITDA is ‪26.75 B‬ USD, and current EBITDA margin is 44.40%. See more stats in AbbVie Inc. financial statements.
Like other stocks, ABBV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AbbVie Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AbbVie Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AbbVie Inc. stock shows the strong buy signal. See more of AbbVie Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.